Difference between revisions of "Pimitespib (Jeselhy)"
Jump to navigation
Jump to search
m |
m (Jwarner moved page Pimitespib (TAS-116) to Pimitespib (Jeselhy): PMDA approval) |
Revision as of 17:34, 6 September 2022
Mechanism of action
From the NCI Drug Dictionary: A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, Hsp90alpha/beta inhibitor TAS-116 specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta.
Preliminary data
Gastrointestinal stromal tumor
- CHAPTER-GIST-301: Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022 Jun 8:S0923-7534(22)01718-5. Epub ahead of print. link to original article PubMed JapicCTI-184094
Also known as
- Code name: TAS-116
- Brand name: Jeselhy